Laman Utama068270 • KRX
add
Celltrion Inc
Tutup sebelumnya
₩173,700.00
Julat hari
₩173,000.00 - ₩176,500.00
Julat tahun
₩157,500.00 - ₩241,000.00
Permodalan pasaran
37.66T KRW
Bilangan Purata
548.33K
Nisbah P/E
191.13
Hasil dividen
0.29%
Berita pasaran
MarketWatch
1 hari lalu
S&P 500 is on a 12-month tear as tariffs threaten 2025 outlook for U.S.
stocks
1.12%
0.35%
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (KRW) | Sep 2024info | Perubahan T/T |
|---|---|---|
Hasil | 881.93B | 31.18% |
Perbelanjaan pengendalian | 255.73B | 148.90% |
Pendapatan bersih | 85.59B | -61.41% |
Margin untung bersih | 9.71 | -70.58% |
Pendapatan bagi setiap syer | 414.00 | -73.48% |
EBITDA | 283.35B | -13.69% |
Kadar cukai berkesan | 52.82% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (KRW) | Sep 2024info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 1.18T | 190.82% |
Jumlah aset | 20.31T | 209.79% |
Jumlah liabiliti | 3.28T | 57.87% |
Jumlah ekuiti | 17.03T | — |
Syer tertunggak | 206.09J | — |
Harga kepada buku | 2.12 | — |
Pulangan pada aset | 2.57% | — |
Pulangan pada modal | 2.70% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (KRW) | Sep 2024info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | 85.59B | -61.41% |
Tunai daripada operasi | 265.31B | 653.96% |
Tunai daripada pelaburan | -136.41B | -38.41% |
Tunai daripada pembiayaan | -47.95B | 61.66% |
Perubahan bersih dalam tunai | 68.24B | 125.70% |
Aliran tunai bebas | 265.58B | 234.44% |
Perihal
Celltrion, Inc. is a biopharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion. Celltrion's founder, Seo Jung-jin, is the richest person in South Korea. Seo Jung-jin, its founder was awarded the 2021 EY World Entrepreneur Of The Year. Wikipedia
CEO
Diasaskan
2002
Tapak web
Pekerja
1,074
